News & Updates
Filter by Specialty:
Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.
Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
27 Nov 2024
Hypo-, hyperthyroidism causally linked to pre-eclampsia
Hyper- and hypothyroidism are causally associated with pre-eclampsia (PE), but PE does not causally influence thyroid dysfunctions, suggest the results of a Mendelian randomization (MR) study.
Hypo-, hyperthyroidism causally linked to pre-eclampsia
27 Nov 2024
Alcoholic drinks up risk of death in young adults with MASLD
Young adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who drink alcoholic beverages are at greater risk of mortality and of having an unhealthy liver, reports a study presented at AASLD 2024.
Alcoholic drinks up risk of death in young adults with MASLD
26 Nov 2024
Presence of mVI/S predicts HCC recurrence after liver resection
Microvascular invasion and/or satellitosis (mVI/S) is independently associated with aggressive recurrence and mortality in hepatocellular carcinoma (HCC) patients treated with liver resection (LR), a recent study has shown.
